TLR agonists have been developed as candidates to improve BC therapy, like Poly(I:C) that activates type I IFN via TLR3 (45, 46), Polyporus polysaccharide (PPS) that activates macrophages through the TLR4/NF-κB signaling pathway (47), TMX-101 and TMX-102 that acts via TLR7 (17, 48), and CpG that induces TLR9 (18) and others (14, 49). This evidence concerns the gene NFKB1 and breast cancer.